Investigational Research Compound
Retatrutide 20MG
$130
20MGListed identity: GIP / GLP-1 / glucagon receptor agonist.
Research overview
Investigational synthetic peptide studied for activity across three metabolic receptor pathways. Research focuses on multi-receptor pharmacology, signaling balance, receptor selectivity, and downstream pathway responses.
Research targets
GIP receptor · GLP-1 receptor · Glucagon receptor
Research status
Retatrutide remains investigational and is not FDA-approved.
Lot documentation
Any documentation should be matched to the exact lot supplied. No testing claim is implied without lot-specific supporting documentation.
RESEARCH USE ONLY. Not for human consumption or medical use. No dosing, reconstitution, injection, administration, treatment, or human-use guidance is provided.